Alex V. Soriano
Distinguished in Urinary Tract Infection (UTI)

Alex V. Soriano

Barcelona, CT, ES 
Distinguished in Urinary Tract Infection (UTI)
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Alex Soriano practices in Barcelona, Spain. Mr. Soriano is rated as a Distinguished expert by MediFind in the treatment of Urinary Tract Infection (UTI). His top areas of expertise are Sepsis, Febrile Neutropenia, Agranulocytosis, Hip Replacement, and Knee Replacement.

His clinical research consists of co-authoring 407 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Urinary Tract Infection (UTI).

Gender
Male

Locations

Barcelona, CT, Spain
Other Locations
Madrid, MD, Spain
Valencia, VC 46022, Spain
Paterna, VC 46980, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase IIb/III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19
A Phase IIb/III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia
Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drugs: Siltuximab, Methylprednisolone
Study Phase: Phase 2
A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers
A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization
Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization
Enrollment Status: Completed
Publish Date: August 23, 2022
Intervention Type: Drug
Study Phase: Phase 1
Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Other, Drug
Study Drug: Maraviroc
Study Phase: Phase 2
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Enrollment Status: Completed
Publish Date: May 27, 2020
Intervention Type: Drug
Study Phase: Phase 3
Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients
Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients
Enrollment Status: Completed
Publish Date: January 17, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

407 Total Publications

Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections.
Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections.
Journal: Future microbiology
Published: December 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Soriano's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile